EpiBiologics

Cancer cells
#EpiBiologics #Financing #Non-small cell lung cancer (NSCLC) #Oncology

Biotech startup raises $107m to advance oncology candidates 

Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies.  The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and… Read More

#Business & Investment #News

Bispecific antibodies
#Antibodies #Antibody engineering #Bispecific Antibodies #EpiBiologics #PEGS Europe

Data shows disease-selective extracellular protein degradation 

EpiBiologics presented new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and will be presenting again at Therapeutics US conference (December 15-18, 2024 in San Diego, California).  … Read More

#News